BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 17609636)

  • 1. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
    Cummings JL
    Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
    Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
    Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
    [No Abstract]   [Full Text] [Related]  

  • 6. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future therapy in Alzheimer's disease.
    van Marum RJ
    Fundam Clin Pharmacol; 2008 Jun; 22(3):265-74. PubMed ID: 18485144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease modifying therapy for AD?
    Golde TE
    J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advanced dementia in Alzheimer's disease and memantine].
    Alberca R
    Rev Neurol; 2005 Feb 1-15; 40(3):173-9. PubMed ID: 15750904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Alzheimer's disease: current and future therapeutic approaches.
    Cummings JL
    Rev Neurol Dis; 2004; 1(2):60-9. PubMed ID: 16400259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.
    Farlow MR; Miller ML; Pejovic V
    Dement Geriatr Cogn Disord; 2008; 25(5):408-22. PubMed ID: 18391487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease: early diagnosis and treatment.
    Chu LW
    Hong Kong Med J; 2012 Jun; 18(3):228-37. PubMed ID: 22665688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
    Van Dam D; De Deyn PP
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):59-69. PubMed ID: 16095884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the effects of memantine on clinical progression in Alzheimer's disease.
    Wilkinson D
    Int J Geriatr Psychiatry; 2012 Aug; 27(8):769-76. PubMed ID: 21964871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not?
    Xiong G; Doraiswamy PM
    Geriatrics; 2005 Jun; 60(6):22-6. PubMed ID: 15948662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.